EntryPoint Capital LLC Makes New Investment in Organon & Co. (NYSE:OGN)

EntryPoint Capital LLC purchased a new stake in Organon & Co. (NYSE:OGN) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 27,939 shares of the company’s stock, valued at approximately $417,000.

Several other hedge funds and other institutional investors also recently modified their holdings of OGN. Vanguard Group Inc. boosted its holdings in Organon & Co. by 0.7% in the 4th quarter. Vanguard Group Inc. now owns 30,401,709 shares of the company’s stock worth $453,593,000 after buying an additional 218,165 shares during the period. Pacer Advisors Inc. boosted its holdings in shares of Organon & Co. by 94,482.1% in the fourth quarter. Pacer Advisors Inc. now owns 11,152,179 shares of the company’s stock worth $166,391,000 after acquiring an additional 11,140,388 shares during the period. Geode Capital Management LLC grew its position in shares of Organon & Co. by 2.0% in the third quarter. Geode Capital Management LLC now owns 4,248,108 shares of the company’s stock valued at $81,288,000 after purchasing an additional 82,220 shares in the last quarter. Charles Schwab Investment Management Inc. grew its position in shares of Organon & Co. by 0.3% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 3,333,703 shares of the company’s stock valued at $49,739,000 after purchasing an additional 10,652 shares in the last quarter. Finally, Private Management Group Inc. raised its stake in shares of Organon & Co. by 11.9% during the 4th quarter. Private Management Group Inc. now owns 2,119,288 shares of the company’s stock valued at $31,620,000 after purchasing an additional 225,420 shares during the period. Institutional investors own 77.43% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have commented on OGN shares. Barclays cut their target price on Organon & Co. from $26.00 to $24.00 and set an “overweight” rating for the company in a research note on Friday, February 14th. TD Cowen upgraded shares of Organon & Co. to a “hold” rating in a research report on Wednesday, January 15th. Finally, Morgan Stanley decreased their target price on shares of Organon & Co. from $17.00 to $16.00 and set an “equal weight” rating on the stock in a report on Friday, February 14th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, two have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Organon & Co. currently has a consensus rating of “Hold” and an average target price of $20.80.

Organon & Co. Stock Performance

Shares of OGN opened at $14.74 on Wednesday. The company has a market cap of $3.80 billion, a PE ratio of 4.43, a price-to-earnings-growth ratio of 0.90 and a beta of 0.76. The company has a current ratio of 1.70, a quick ratio of 1.21 and a debt-to-equity ratio of 17.73. The stock has a 50-day moving average price of $15.41 and a 200-day moving average price of $16.33. Organon & Co. has a 12-month low of $13.87 and a 12-month high of $23.10.

Organon & Co. (NYSE:OGN) last announced its earnings results on Thursday, February 13th. The company reported $0.83 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.92 by ($0.09). Organon & Co. had a net margin of 13.49% and a return on equity of 431.62%. The company had revenue of $1.59 billion for the quarter, compared to the consensus estimate of $1.57 billion. As a group, equities analysts forecast that Organon & Co. will post 3.68 earnings per share for the current fiscal year.

Organon & Co. Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, March 13th. Investors of record on Monday, February 24th were given a $0.28 dividend. The ex-dividend date of this dividend was Monday, February 24th. This represents a $1.12 annualized dividend and a yield of 7.60%. Organon & Co.’s dividend payout ratio (DPR) is presently 33.63%.

Organon & Co. Company Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.